Indaptus Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.09 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $2.12Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $282.5M Enterprise Value $281M Shares Outstanding 133.2M diluted Next Earnings Date13 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Indaptus Therapeutics is undergoing a major corporate transition following a change of control in early 2026. While its proprietary immunotherapy platform (Decoy20) has shown early promise, clinical trials have been paused for evaluation, and the company faces an urgent need for capital with cash reserves down to $1.5 million as of March 31, 2026. The appointment of Junyi Dai as CEO and Chairman, alongside significant board turnover, introduces strategic uncertainty. Investors should maintain a Hold position until there is clear visibility on capital raising and the resumption of clinical development. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The company fails to raise capital on acceptable terms, leading to severe dilution or insolvency. Clinical trials remain indefinitely suspended, and the stock faces delisting from Nasdaq due to low market value of listed securities. Base CaseCentral scenario The company successfully secures dilutive financing or a strategic partnership to extend its cash runway, allowing new management to resume clinical trials for Decoy20. Valuation remains constrained by execution risks and dilution. Bull CaseUpside scenario The bull case for Indaptus Therapeutics centers on the clinical validation of its lead multi-target immunotherapy candidate, Decoy20. Successful Phase 1/2 clinical trial outcomes demonstrating safety and efficacy in activating both innate and adaptive immune responses against solid tumors could validate its proprietary platform. This clinical progress is expected to drive significant valuation upside toward analyst price targets (ranging from $5.00 to $12.00) and attract strategic biopharmaceutical partnerships, providing non-dilutive funding and validating the technology. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |